Comparative Pharmacology
Head-to-head clinical analysis: CANAGLIFLOZIN versus GLYXAMBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANAGLIFLOZIN versus GLYXAMBI.
CANAGLIFLOZIN vs GLYXAMBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin increases incretin hormones (GLP-1, GIP), enhancing insulin release and decreasing glucagon levels in a glucose-dependent manner.
100 mg orally once daily; may increase to 300 mg once daily for additional glycemic control.
10 mg/5 mg orally once daily (empagliflozin/linagliptin). May increase to 25 mg/5 mg once daily if tolerated.
None Documented
None Documented
Clinical Note
moderateCanagliflozin + Gatifloxacin
"Canagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateCanagliflozin + Rosoxacin
"Canagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateCanagliflozin + Levofloxacin
"Canagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateCanagliflozin + Trovafloxacin
"Canagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life: 10.6–13.1 hours (single dose); steady-state: ~12.9 hours. Clinically, supports once-daily dosing with sustained SGLT2 inhibition over 24 hours.
Empagliflozin: Terminal half-life ~12.4 hours allows once-daily dosing. Linagliptin: Terminal half-life >100 hours, but pharmacodynamic effect correlates with DPP-4 inhibition rather than plasma levels.
Renal: 33% (primarily tubular secretion, ~1% unchanged in urine; remainder as glucuronide metabolites); Fecal: 52% (as parent drug and metabolites); Biliary: minor (enterohepatic circulation suspected but not quantified).
Empagliflozin: Approximately 95.6% excreted in feces (41.2% as unchanged drug) and 54.4% in urine (19.8% as unchanged). Linagliptin: 84% excreted in feces via enterohepatic circulation (80% as parent drug) and 5% in urine.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor/DPP-4 Inhibitor Combination Antidiabetic